Future of Idera's Cambridge office uncertain after failed merger
July 11, 2018 at 11:56 AM EDT
The Cambridge-based immunology biotech's future is murky after a planned merger with drug developer BioCryst fell through this week.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.